Thalassemia-free and graft-versus-host-free survival: outcomes of hematopoietic stem cell transplantation for thalassemia major, Turkish experience.
Journal
Bone marrow transplantation
ISSN: 1476-5365
Titre abrégé: Bone Marrow Transplant
Pays: England
ID NLM: 8702459
Informations de publication
Date de publication:
05 2022
05 2022
Historique:
received:
15
09
2021
accepted:
08
02
2022
revised:
07
02
2022
pubmed:
26
2
2022
medline:
14
5
2022
entrez:
25
2
2022
Statut:
ppublish
Résumé
We report the national data on the outcomes of hematopoietic stem cell transplantation (HSCT) for thalassemia major (TM) patients in Turkey on behalf of the Turkish Pediatric Stem Cell Transplantation Group. We retrospectively enrolled 1469 patients with TM who underwent their first HSCT between 1988 and 2020 in 25 pediatric centers in Turkey. The median follow-up duration and transplant ages were 62 months and 7 years, respectively; 113 patients had chronic graft versus host disease (cGVHD) and the cGVHD rate was 8.3% in surviving patients. Upon the last visit, 30 patients still had cGvHD (2.2%). The 5-year overall survival (OS), thalassemia-free survival (TFS) and thalassemia-GVHD-free survival (TGFS) rates were 92.3%, 82.1%, and 80.8%, respectively. cGVHD incidence was significantly lower in the mixed chimerism (MC) group compared to the complete chimerism (CC) group (p < 0.001). In survival analysis, OS, TFS, and TGFS rates were significantly higher for transplants after 2010. TFS and TGFS rates were better for patients under 7 years and at centers that had performed over 100 thalassemia transplants. Transplants from matched unrelated donors had significantly higher TFS rates. We recommend HSCT before 7 years old in thalassemia patients who have a matched donor for improved outcomes.
Identifiants
pubmed: 35210564
doi: 10.1038/s41409-022-01613-w
pii: 10.1038/s41409-022-01613-w
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
760-767Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Nature Limited.
Références
Baronciani D, Angelucci E, Potschger U, Gaziev J, Yesilipek A, Zecca M, et al. Hemopoietic stem cell transplantation in thalassemia: a report from the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Registry, 2000-2010. Bone Marrow Transpl. 2016;51:536–41.
doi: 10.1038/bmt.2015.293
Angelucci E, Matthes-Martin S, Baronciani D, Bernaudin F, Bonanomi S, Cappellini MD, et al. Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel. Haematologica. 2014;99:811–20.
doi: 10.3324/haematol.2013.099747
Yesilipek MA, Ertem M, Cetin M, Oniz H, Kansoy S, Tanyeli A, et al. HLA-matched family hematopoetic stem cell transplantation in children with beta thalassemia major: the experience of the Turkish Pediatric Bone Marrow Transplantation Group. Pediatr Transplant 2012;16:846–51.
doi: 10.1111/j.1399-3046.2012.01778.x
Angelucci E. Complication free survival long-term after hemopoietic cell transplantation in thalassemia. Haematologica. 2018;103:1094–6.
doi: 10.3324/haematol.2018.196071
Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974;18:295–304.
doi: 10.1097/00007890-197410000-00001
Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11:945–56.
doi: 10.1016/j.bbmt.2005.09.004
Lucarelli G, Galimberti M, Polchi P, Angelucci E, Baronciani D, Giardini C, et al. Marrow transplantation in patients with thalassemia responsive to iron chelation therapy. N Engl J Med. 1993;329:840–4.
doi: 10.1056/NEJM199309163291204
Sabloff M, Chandy M, Wang Z, Logan BR, Ghavamzadeh A, Li CK, et al. HLA-matched sibling bone marrow transplantation for beta-thalassemia major. Blood. 2011;117:1745–50.
doi: 10.1182/blood-2010-09-306829
La Nasa G, Caocci G, Efficace F, Dessi C, Vacca A, Piras E, et al. Long-term health-related quality of life evaluated more than 20 years after hematopoietic stem cell transplantation for thalassemia. Blood. 2013;122:2262–70.
doi: 10.1182/blood-2013-05-502658
Rahal I, Galambrun C, Bertrand Y, Garnier N, Paillard C, Frange P, et al. Late effects after hematopoietic stem cell transplantation for beta-thalassemia major: the French national experience. Haematologica. 2018;103:1143–9.
doi: 10.3324/haematol.2017.183467
Uygun V, Tayfun F, Akcan M, Karasu GT, Kupesiz A, Hazar V, et al. Quality of life assessment in hematopoietic stem cell transplantation performed on thalassemia major patients. Pediatr Hematol Oncol. 2012;29:461–71.
doi: 10.3109/08880018.2012.693577
Ramprakash S, Agarwal R, Dhanya R, Marwah P, Soni R, Yaqub N, et al. Low-cost matched sibling bone marrow transplant for standard-risk thalassemia in a limited-resource setting. Pediatr Hematol Oncol J 2017;2:107–13. 2017/12/01/
doi: 10.1016/j.phoj.2017.12.002
Li Q, Luo J, Zhang Z, Liu L, Luo L, Yang G, et al. G-CSF-Mobilized blood and bone marrow grafts as the source of stem cells for HLA-identical sibling transplantation in patients with thalassemia major. Biol Blood Marrow Transplant. 2019;25:2040–4.
doi: 10.1016/j.bbmt.2019.06.009
Lai X, Liu L, Zhang Z, Shi L, Yang G, Wu M, et al. Hepatic veno-occlusive disease/sinusoidal obstruction syndrome after hematopoietic stem cell transplantation for thalassemia major: incidence, management, and outcome. Bone Marrow Transplant. 2021;56:1635–41. 2021/07/01
doi: 10.1038/s41409-021-01233-w
van Besien K, Dew A, Lin S, Joseph L, Godley LA, Larson RA, et al. Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence. Leuk Lymphoma. 2009;50:1809–17.
doi: 10.3109/10428190903200790
Galambrun C, Pondarre C, Bertrand Y, Loundou A, Bordigoni P, Frange P, et al. French multicenter 22-year experience in stem cell transplantation for beta-thalassemia major: lessons and future directions. Biol Blood Marrow Transplant. 2013;19:62–8.
doi: 10.1016/j.bbmt.2012.08.005
Korula A, Devasia AJ, Fouzia NA, Nisham PN, Kulkarni U, Lakshmi KM, et al. Outcomes following allogeneic stem cell transplantation using non-sibling family donors. Indian J Hematol Blood Transfus. 2019;35:43–9.
doi: 10.1007/s12288-018-0988-z
Gaziev J, Marziali M, Isgro A, Sodani P, Paciaroni K, Gallucci C, et al. Bone marrow transplantation for thalassemia from alternative related donors: improved outcomes with a new approach. Blood. 2013;122:2751–6.
doi: 10.1182/blood-2013-07-513473
Aydogdu S, Toret E, Aksoy BA, Aydin MF, Cipe FE, Bozkurt C, et al. Comparison of hematopoietic stem cell transplantation results in patients with beta-thalassemia major from three different graft types. Hemoglobin. 2021;45:25–9.
doi: 10.1080/03630269.2021.1872611
La Nasa G, Argiolu F, Giardini C, Pession A, Fagioli F, Caocci G, et al. Unrelated bone marrow transplantation for beta-thalassemia patients: the experience of the Italian Bone Marrow Transplant Group. Ann NY Acad Sci. 2005;1054:186–95.
doi: 10.1196/annals.1345.023
Li C, Mathews V, Kim S, George B, Hebert K, Jiang H, et al. Related and unrelated donor transplantation for beta-thalassemia major: results of an international survey. Blood Adv. 2019;3:2562–70.
doi: 10.1182/bloodadvances.2019000291
Anurathapan U, Hongeng S, Pakakasama S, Songdej D, Sirachainan N, Pongphitcha P, et al. Hematopoietic stem cell transplantation for severe thalassemia patients from haploidentical donors using a novel conditioning regimen. Biol Blood Marrow Transplant. 2020;26:1106–12.
doi: 10.1016/j.bbmt.2020.01.002
Oevermann L, Schulte JH, Hundsdorfer P, Hakimeh D, Kogel F, Lang P, et al. HLA-haploidentical hematopoietic stem cell transplantation in pediatric patients with hemoglobinopathies: current practice and new approaches. Bone Marrow Transplant. 2019;54:743–8.
doi: 10.1038/s41409-019-0598-x
Yesilipek MA, Hazar V, Kupesiz A, Kizilors A, Uguz A, Yegin O. Peripheral blood stem cell transplantation in children with beta-thalassemia. Bone Marrow Transplant. 2001;28:1037–40.
doi: 10.1038/sj.bmt.1703284
Ghavamzadeh A, Kasaeian A, Rostami T, Kiumarsi A. Comparable outcomes of allogeneic peripheral blood versus bone marrow hematopoietic stem cell transplantation in major thalassemia: a multivariate long-term cohort analysis. Biol Blood Marrow Transplant. 2019;25:307–12.
doi: 10.1016/j.bbmt.2018.09.026
Sun L, Wang N, Chen Y, Tang L, Xing C, Lu N, et al. Unrelated donor peripheral blood stem cell transplantation for patients with beta-thalassemia major based on a novel conditioning regimen. Biol Blood Marrow Transplant. 2019;25:1592–6.
doi: 10.1016/j.bbmt.2019.03.028
Locatelli F, Rocha V, Reed W, Bernaudin F, Ertem M, Grafakos S, et al. Related umbilical cord blood transplantation in patients with thalassemia and sickle cell disease. Blood. 2003;101:2137–43.
doi: 10.1182/blood-2002-07-2090
Strocchio L, Locatelli F. Hematopoietic stem cell transplantation in thalassemia. Hematol Oncol Clin North Am. 2018;32:317–28.
doi: 10.1016/j.hoc.2017.11.011
Kanathezhath B, Walters MC. Umbilical cord blood transplantation for thalassemia major. Hematol Oncol Clin North Am. 2010;24:1165–77.
doi: 10.1016/j.hoc.2010.08.006
Ruggeri A, Eapen M, Scaravadou A, Cairo MS, Bhatia M, Kurtzberg J, et al. Umbilical cord blood transplantation for children with thalassemia and sickle cell disease. Biol Blood Marrow Transplant. 2011;17:1375–82.
doi: 10.1016/j.bbmt.2011.01.012
Tucunduva L, Volt F, Cunha R, Locatelli F, Zecca M, Yesilipek A, et al. Combined cord blood and bone marrow transplantation from the same human leucocyte antigen-identical sibling donor for children with malignant and non-malignant diseases. Br J Haematol. 2015;169:103–10.
doi: 10.1111/bjh.13267
Choudhary D, Doval D, Sharma SK, Khandelwal V, Setia R, Handoo A. Allogenic hematopoietic cell transplantation in thalassemia major: a single-center retrospective analysis from India. J Pediatr Hematol Oncol. 2019;41:e296–e301.
doi: 10.1097/MPH.0000000000001475
Alonso L, Gonzalez-Vicent M, Belendez C, Badell I, Sastre A, Rodriguez-Villa A, et al. Hematopoietic stem cell transplantation in pediatric patients with thalassemia and sickle cell disease: an experience of the Spanish Working Group for Bone Marrow Transplantation in Children (GETMON). Med Clin. 2019;152:135–40.
doi: 10.1016/j.medcli.2018.05.013
Caocci G, Orofino MG, Vacca A, Piroddi A, Piras E, Addari MC, et al. Long-term survival of beta thalassemia major patients treated with hematopoietic stem cell transplantation compared with survival with conventional treatment. Am J Hematol. 2017;92:1303–10.
doi: 10.1002/ajh.24898